… growth factor (EGF) belongs to a family of related peptides (EGF-like growth factor), which
include transforming growth factor o (TGFo… EGF-like growth factors bind to activate one or more …

… from tissue resected 68 days after the initiation of erlotinib treatment, after the patient was
off study and no longer treated with erlotinib. There was not sufficient tissue to complete all …

… Erlotinib (Tarceva®) has demonstrated a survival benefit in … erlotinib, epidermal growth
factor receptor (EGFR) protein expression may provide a basis for selecting patients for treatment …

… of rash during treatment with the epidermal growth factor receptor inhibitor erlotinib and
improved … (single agent in non–small-cell lung cancer, n = 444 in erlotinib group and n = 229 in …

… growth factor receptor expression and mutation status. This article reviews the current clinical
status of erlotinib… in survival associated with erlotinib treatment, as compared with placebo, …

… cell carcinoma; erlotinib; gefitinib; and epidermal growth factor receptor were combined with
… cell lung; Iressa; gefitinib; ZD1839; Tarceva; erlotinib; OSI774; and EGFR-TK. These terms …

… to undergo erlotinib treatment were … start of erlotinib treatment can identify erlotinib responders
and nonresponders. These findings are relevant because early identification of treatment …

… growth factor receptor (EGFR) mutations have been associated with tumor response to
treatment … The implications of EGFR mutations in patients treated with EGFR inhibitors plus first-…

… Role of IGF-IR signaling pathways in the development of resistance to erlotinib treatment
in NSCLC cells. To investigate the mechanisms involved in the sensitivity of NSCLC cells to …

… Erlotinib (Tarceva) is an orally available HER1 (epidermal growth factor receptor, EGFR)
tyrosine kinase inhibitor advancing through clinical trials for the treatment of a range of human …